A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
A broad class of substances encompassing all those that do not include carbon and its derivatives as their principal elements. However, carbides, carbonates, cyanides, cyanates, and carbon disulfide are included in this class.
A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)
A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
The representation of the phylogenetically oldest part of the corpus striatum called the paleostriatum. It forms the smaller, more medial part of the lentiform nucleus.
Slow or diminished movement of body musculature. It may be associated with BASAL GANGLIA DISEASES; MENTAL DISORDERS; prolonged inactivity due to illness; and other conditions.
Continuous involuntary sustained muscle contraction which is often a manifestation of BASAL GANGLIA DISEASES. When an affected muscle is passively stretched, the degree of resistance remains constant regardless of the rate at which the muscle is stretched. This feature helps to distinguish rigidity from MUSCLE SPASTICITY. (From Adams et al., Principles of Neurology, 6th ed, p73)
Lens-shaped structure on the inner aspect of the INTERNAL CAPSULE. The SUBTHALAMIC NUCLEUS and pathways traversing this region are concerned with the integration of somatic motor function.
Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce DOPAMINE, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored MELANIN is a by-product of dopamine synthesis.
A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.
Uncrossed tracts of motor nerves from the brain to the anterior horns of the spinal cord, involved in reflexes, locomotion, complex movements, and postural control.
Abnormal involuntary movements which primarily affect the extremities, trunk, or jaw that occur as a manifestation of an underlying disease process. Conditions which feature recurrent or persistent episodes of dyskinesia as a primary manifestation of disease may be referred to as dyskinesia syndromes (see MOVEMENT DISORDERS). Dyskinesias are also a relatively common manifestation of BASAL GANGLIA DISEASES.
Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE.
Large subcortical nuclear masses derived from the telencephalon and located in the basal regions of the cerebral hemispheres.
An inhibitor of DOPA DECARBOXYLASE, preventing conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no antiparkinson actions by itself.
Persistent and disabling ANXIETY.
Those disorders that have a disturbance in mood as their predominant feature.
Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.
Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.
A group of inherited and sporadic disorders which share progressive ataxia in combination with atrophy of the CEREBELLUM; PONS; and inferior olivary nuclei. Additional clinical features may include MUSCLE RIGIDITY; NYSTAGMUS, PATHOLOGIC; RETINAL DEGENERATION; MUSCLE SPASTICITY; DEMENTIA; URINARY INCONTINENCE; and OPHTHALMOPLEGIA. The familial form has an earlier onset (second decade) and may feature spinal cord atrophy. The sporadic form tends to present in the fifth or sixth decade, and is considered a clinical subtype of MULTIPLE SYSTEM ATROPHY. (From Adams et al., Principles of Neurology, 6th ed, p1085)
Therapy for MOVEMENT DISORDERS, especially PARKINSON DISEASE, that applies electricity via stereotactic implantation of ELECTRODES in specific areas of the BRAIN such as the THALAMUS. The electrodes are attached to a neurostimulator placed subcutaneously.
An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
Categorical classification of MENTAL DISORDERS based on criteria sets with defining features. It is produced by the American Psychiatric Association. (DSM-IV, page xxii)

The genetics of disorders with synuclein pathology and parkinsonism. (1/846)

Despite being considered the archetypal non-genetic neurological disorder, genetic analysis of Parkinson's disease has shown that there are at least three genetic loci. Furthermore, these analyses have suggested that the phenotype of the pathogenic loci is wider than simple Parkinson's disease and may include Lewy body dementia and some forms of essential tremor. Identification of alpha-synuclein as the first of the loci involved in Parkinson's disease and the identification of this protein in pathological deposits in other disorders has led to the suggestion that it may share pathogenic mechanisms with multiple system atrophy, Alzheimer's disease and prion disease and that these mechanisms are related to a synuclein pathway to cell death. Finally, genetic analysis of the synuclein diseases and the tau diseases may indicate that this synuclein pathway is an alternative to the tau pathway to cell death.  (+info)

Evaluation of the substantia nigra in patients with Parkinsonian syndrome accomplished using multishot diffusion-weighted MR imaging. (2/846)

BACKGROUND AND PURPOSE: Although it is important to evaluate the substantia nigra in patients with parkinsonian syndrome, it is difficult to depict its anatomy, even by MR imaging. Using anatomic studies of the direction of nerve fibers around the substantia nigra, we attempted to depict this entity with multishot diffusion-weighted MR imaging to evaluate its topographic changes in patients with Parkinson's disease and secondary parkinsonism. METHODS: We measured the substantia nigra on 72 diffusion-weighted axial MR images obtained in 36 healthy control subjects, on 47 images obtained in 25 patients with Parkinson's disease, and on 10 images obtained in five patients with secondary parkinsonism. We considered the width of the minor axis of the substantia nigra as its "thickness," which appeared as a crescent-shaped region in the midbrain. RESULTS: Diffusion-weighted imaging portrayed the substantia nigra distinctly better than did T2-weighted imaging, because the surrounding white matter appeared as an area of high signal intensity. The mean (+/- SD) thickness values of the substantia nigra were 5.1+/-0.89 mm in control subjects, 4.8+/-0.75 mm in patients with Parkinson's disease, and 3.4+/-0.53 mm in patients with secondary parkinsonism. CONCLUSION: Multishot diffusion-weighted imaging is a better imaging technique than T2-weighted imaging for demonstrating a change in size of the substantia nigra in vivo. The substantia nigra is not reduced in size in patients with Parkinson's disease, but it is reduced in patients with secondary parkinsonism.  (+info)

Motor deficits and schizophrenia: the evidence from neuroleptic-naive patients and populations at risk. (3/846)

Patients with schizophrenia and high-risk populations have elevated rates of eye movement abnormalities. However, it is not known whether these abnormalities are specific to eye movements or whether they are also found in more traditional domains of motor control. Most studies examining the motor function of patients with schizophrenia have involved patients treated with medication; abnormalities in motor function could be a result of treatment rather than the disease itself. If motor abnormalities are related to schizophrenia, they should also be found in neuroleptic-naive patients and possibly in high-risk populations in whom eye movement abnormalities are also observed. We reviewed relevant empirical papers published in the last 35 years. Results suggest that approximately one-fifth of neuroleptic-naive patients with schizophrenia have increased rates of parkinsonism and neurological soft signs. In high-risk populations, replicated findings include delayed motor development in preschizophrenia subjects, and poor motor skills in the offspring of patients with schizophrenia. In first-degree relatives, increased rates of neurological soft signs were reported. These findings suggest that motor abnormalities are not limited to eye movements and may constitute markers of vulnerability. The literature has several weaknesses that should be addressed in future studies.  (+info)

Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. (4/846)

OBJECTIVE: Although both orthostatic hypotension and urinary incontinence have been reported in a number of parkinsonian syndromes, such as Parkinson's disease (PD), multiple system atrophy (MSA), dementia with Lewy bodies (DLB), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP), differences in the evolution of these features have not been studied systematically in pathologically confirmed cases. METHODS: 77 cases with pathologically confirmed parkinsonian syndromes (PD, n=11; MSA, n=15; DLB, n=14; CBD, n=13; PSP, n=24), collected up to 1994, formed the basis for a multicentre clinicopathological study organised by the NINDS to improve the differential diagnosis of parkinsonian disorders. The present study determined the time course-that is, latency to onset and duration from onset to death, of symptomatic orthostatic hypotension, and urinary incontinence in the NINDS series. Furthermore, the diagnostic validity of a predefined latency to onset within 1 year of disease onset of symptomatic orthostatic hypotension or urinary incontinence was analysed. RESULTS: Significant group differences for latency, but not duration, of symptomatic orthostatic hypotension and urinary incontinence were found. Latencies to onset of either feature were short in patients with MSA, intermediate in patients with DLB, CBD, and PSP, and long in those with PD. Symptomatic orthostatic hypotension occurring within the first year after disease onset predicted MSA in 75% of cases; early urinary incontinence was less predictive for MSA (56%). CONCLUSION: Latency to onset, but not duration, of symptomatic orthostatic hypotension or urinary incontinence differentiates PD from other parkinsonian syndromes, particularly MSA.  (+info)

FTDP-17 tau mutations decrease the susceptibility of tau to calpain I digestion. (5/846)

Frontal temporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is caused by splice site and missense mutations in the tau gene, and characterized by the accumulation of filamentous tau in cerebral neurons and glia. The missense mutations reduce the ability of tau to promote microtubule assembly and increase the ability of tau to form filaments. In this report we demonstrate that mutants V337M and R406W are less susceptible than mutant P301L or corresponding wild type tau to degradation by calpain I. The differences were at least in part due to changes in accessibility of a cleavage site located about 100 amino acids off the carboxy-terminus. The results suggest that the pathogenesis of some forms of FTDP-17 may involve tau accumulation due to decreased proteolytic degradation.  (+info)

Structural basis for recognition of the RNA major groove in the tau exon 10 splicing regulatory element by aminoglycoside antibiotics. (6/846)

Drug-like molecules that bind RNA with sequence selectivity would provide valuable tools to elucidate gene expression pathways and new avenues to the treatment of degenerative and chronic conditions. Efforts at discovering such agents have been hampered, until recently, by the limited knowledge of RNA recognition principles. Several recent structures of aminoglycoside-RNA complexes have begun to reveal the structural basis for RNA-drug recognition. However, the absence of suitable chemical scaffolds known to bind the RNA major groove, where specificity could be provided by the diversity of functional groups exposed on the RNA bases, has represented a major obstacle. Here we report an investigation of the structural basis for recognition of an RNA stem-loop by neomycin, a naturally occurring aminoglycoside antibiotic. We found that neomycin binds the RNA stem-loop that regulates alternative splicing of exon 10 within the gene coding for human tau protein. Mutations within this splicing regulatory element destabilise the RNA structure and cause frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17), an autosomal dominant condition leading to neurodegeneration and death. The three-dimensional structure of the RNA-neomycin complex shows interaction of the drug in the major groove of the short RNA duplex, where familial mutations cluster. Analysis of the structure shows how aminoglycosides and related drugs bind to the RNA major groove, adding to our understanding of the principles of drug-RNA recognition.  (+info)

D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys. (7/846)

Selective D(1) dopamine receptor agonists exert antiparkinsonian effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model of Parkinson's disease and in human Parkinson's disease. Motor impairment in idiopathic Parkinson's disease progresses from mild to severe, but the therapeutic potential of D(1) dopamine receptor agonists in early and advanced stages of parkinsonism is not known. To compare the effectiveness of D(1) agonists at different levels of impairment, we developed a model of mild and advanced parkinsonism in nonhuman primates and a rating scale that differentiated the two models. D(1) dopamine receptor agonists (SKF 81297, dihydrexidine) and D(2) dopamine receptor agonists [quinelorane, (+)-PHNO were administered to monkeys (Macaca fascicularis) displaying either mild parkinsonism (two doses of 0.6 mg/kg i.v. MPTP 1 month apart) or advanced parkinsonism (three doses of 0.6 mg/kg i.v. MPTP within 10 days). In normal monkeys (n = 3), SKF 81297 and dihydrexidine did not promote increased motor activity. In advanced parkinsonism (n = 4), D(1) and D(2) dopamine agonists effectively reversed the motor deficits. In contrast, the therapeutic benefits of D(1) agonists SKF 81297 and dihydrexidine were relatively limited in mild parkinsonism (n = 4). The D(2) agonists quinelorane and (+)-PHNO alleviated some symptoms in mild parkinsonism but also reduced balance and induced more dyskinesias than did D(1) agonists. Mild and advanced parkinsonism in nonhuman primates can be produced with fixed dosing regimens of MPTP. Based on the therapeutic efficacy and side effect profiles derived from these models, D(1) agonists are more promising for the treatment of advanced than of mild Parkinson's disease.  (+info)

Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism. (8/846)

Evaluation of therapies for parkinsonism by dopamine receptor SPECT requires a reproducible, optimized quantitation technique. This study presents a new, objective, automated technique for semiquantitative analysis of dopamine receptor density, as applied to the differential diagnosis of parkinsonism. METHODS: Dopamine receptor density measured by 123I-iodobenzamide (IBZM) SPECT was retrospectively analyzed in nonidiopathic parkinsonism (NIPS), in Parkinson's disease (PD), and in healthy volunteers (n = 19, 38, and 13, respectively). A mean template was created from coregistered control studies. Registration errors were assessed using studies with simulated binding deficits. Patient studies were registered to the mean template, and striatal binding was calculated from a corresponding map of 3-dimensional regions of interest (ROIs). The striatal binding ratio and deficits determined by voxelwise comparison with the normal template were investigated and tested with various 3-dimensional ROI sizes and positions. Separation of patient groups was determined by tscore after automatically processing all studies. Results were compared with manual ROI analyses. RESULTS: The automatic method was completely reproducible in 64 of 70 cases. The best diagnostic discriminator was the minimum binding ratio of the 2 striatal nuclei, with the following values: NIPS, 1.33+/-0.13; PD, 1.50+/-0.12; healthy volunteers, 1.49+/-0.08 (+/-SD). The deficit size from voxelwise analysis was: NIPS, 20.5+/-8.2 mL; PD, 9.5+/-8.3; healthy volunteers, 8.9+/-6.0 (+/-SD). The accuracy, measured by receiver operating characteristic areas, was 0.85+/-0.05, 0.77+/-0.06, and 0.80+/-0.06 (+/-SE) for the optimal predictor (automated) and 2 blinded observers (manual), respectively. CONCLUSION: A new 3-dimensional, automated technique has been developed to semiquantitate receptor density that dramatically improves reproducibility. The optimal diagnostic discriminator of parkinsonism determined by the automatic technique has good accuracy compared with the manual technique.  (+info)

Parkinsonian disorders are a group of neurological conditions characterized by motor symptoms such as bradykinesia (slowness of movement), rigidity, resting tremor, and postural instability. These symptoms are caused by the degeneration of dopamine-producing neurons in the brain, particularly in the substantia nigra pars compacta.

The most common Parkinsonian disorder is Parkinson's disease (PD), which is a progressive neurodegenerative disorder. However, there are also several other secondary Parkinsonian disorders, including:

1. Drug-induced parkinsonism: This is caused by the use of certain medications, such as antipsychotics and metoclopramide.
2. Vascular parkinsonism: This is caused by small vessel disease in the brain, which can lead to similar symptoms as PD.
3. Dementia with Lewy bodies (DLB): This is a type of dementia that shares some features with PD, such as the presence of alpha-synuclein protein clumps called Lewy bodies.
4. Progressive supranuclear palsy (PSP): This is a rare brain disorder that affects movement, gait, and eye movements.
5. Multiple system atrophy (MSA): This is a progressive neurodegenerative disorder that affects multiple systems in the body, including the autonomic nervous system, motor system, and cerebellum.
6. Corticobasal degeneration (CBD): This is a rare neurological disorder that affects both movement and cognition.

It's important to note that while these disorders share some symptoms with PD, they have different underlying causes and may require different treatments.

I must clarify that "Inorganic Chemicals" is a broad term related to the field of chemistry and not specifically within the realm of medicine. However, I can provide a general definition for you:

Inorganic chemicals are chemical substances that primarily consist of matter other than carbon-based compounds. They include metallic and non-metallic elements, along with their compounds, excluding carbon-hydrogen bonds (organic compounds). Examples of inorganic chemicals are salts, acids, and bases, as well as metal alloys and oxides.

In the context of medicine, certain inorganic chemicals can be used in medical treatments, such as lithium carbonate for bipolar disorder or potassium chloride as an electrolyte replenisher. However, some inorganic chemicals can also pose health risks depending on the type and level of exposure. For instance, lead and mercury are toxic heavy metals that can cause serious health problems if ingested or inhaled.

Progressive Supranuclear Palsy (PSP) is a rare neurological disorder characterized by the progressive degeneration of brain cells that regulate movement, thoughts, behavior, and eye movements. The term "supranuclear" refers to the location of the damage in the brain, specifically above the level of the "nuclei" which are clusters of nerve cells that control voluntary movements.

The most common early symptom of PSP is a loss of balance and difficulty coordinating eye movements, particularly vertical gaze. Other symptoms may include stiffness or rigidity of muscles, slowness of movement, difficulty swallowing, changes in speech and writing, and cognitive decline leading to dementia.

PSP typically affects people over the age of 60, and its progression can vary from person to person. Currently, there is no cure for PSP, and treatment is focused on managing symptoms and maintaining quality of life.

Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects multiple systems in the body. It is characterized by a combination of symptoms including Parkinsonism (such as stiffness, slowness of movement, and tremors), cerebellar ataxia (lack of muscle coordination), autonomic dysfunction (problems with the autonomic nervous system which controls involuntary actions like heart rate, blood pressure, sweating, and digestion), and pyramidal signs (abnormalities in the corticospinal tracts that control voluntary movements).

The disorder is caused by the degeneration of nerve cells in various parts of the brain and spinal cord, leading to a loss of function in these areas. The exact cause of MSA is unknown, but it is thought to involve a combination of genetic and environmental factors. There is currently no cure for MSA, and treatment is focused on managing symptoms and improving quality of life.

Parkinson's disease is a progressive neurodegenerative disorder that affects movement. It is characterized by the death of dopamine-producing cells in the brain, specifically in an area called the substantia nigra. The loss of these cells leads to a decrease in dopamine levels, which results in the motor symptoms associated with Parkinson's disease. These symptoms can include tremors at rest, stiffness or rigidity of the limbs and trunk, bradykinesia (slowness of movement), and postural instability (impaired balance and coordination). In addition to these motor symptoms, non-motor symptoms such as cognitive impairment, depression, anxiety, and sleep disturbances are also common in people with Parkinson's disease. The exact cause of Parkinson's disease is unknown, but it is thought to be a combination of genetic and environmental factors. There is currently no cure for Parkinson's disease, but medications and therapies can help manage the symptoms and improve quality of life.

Levodopa, also known as L-dopa, is a medication used primarily in the treatment of Parkinson's disease. It is a direct precursor to the neurotransmitter dopamine and works by being converted into dopamine in the brain, helping to restore the balance between dopamine and other neurotransmitters. This helps alleviate symptoms such as stiffness, tremors, spasms, and poor muscle control. Levodopa is often combined with carbidopa (a peripheral decarboxylase inhibitor) to prevent the conversion of levodopa to dopamine outside of the brain, reducing side effects like nausea and vomiting.

Secondary Parkinson's disease, also known as acquired or symptomatic Parkinsonism, is a clinical syndrome characterized by the signs and symptoms of classic Parkinson's disease (tremor at rest, rigidity, bradykinesia, and postural instability) but caused by a known secondary cause. These causes can include various conditions such as brain injuries, infections, drugs or toxins, metabolic disorders, and vascular damage. The underlying pathology of secondary Parkinson's disease is different from that of classic Parkinson's disease, which is primarily due to the degeneration of dopamine-producing neurons in a specific area of the brain called the substantia nigra pars compacta.

Antiparkinson agents are a class of medications used to treat the symptoms of Parkinson's disease and related disorders. These agents work by increasing the levels or activity of dopamine, a neurotransmitter in the brain that is responsible for regulating movement and coordination.

There are several types of antiparkinson agents, including:

1. Levodopa: This is the most effective treatment for Parkinson's disease. It is converted to dopamine in the brain and helps to replace the missing dopamine in people with Parkinson's.
2. Dopamine agonists: These medications mimic the effects of dopamine in the brain and can be used alone or in combination with levodopa. Examples include pramipexole, ropinirole, and rotigotine.
3. Monoamine oxidase B (MAO-B) inhibitors: These medications block the breakdown of dopamine in the brain and can help to increase its levels. Examples include selegiline and rasagiline.
4. Catechol-O-methyltransferase (COMT) inhibitors: These medications block the breakdown of levodopa in the body, allowing it to reach the brain in higher concentrations. Examples include entacapone and tolcapone.
5. Anticholinergic agents: These medications block the action of acetylcholine, another neurotransmitter that can contribute to tremors and muscle stiffness in Parkinson's disease. Examples include trihexyphenidyl and benztropine.

It is important to note that antiparkinson agents can have side effects, and their use should be carefully monitored by a healthcare professional. The choice of medication will depend on the individual patient's symptoms, age, overall health, and other factors.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a chemical compound that can cause permanent parkinsonian symptoms. It is not a medication or a treatment, but rather a toxin that can damage the dopamine-producing neurons in the brain, leading to symptoms similar to those seen in Parkinson's disease.

MPTP itself is not harmful, but it is metabolized in the body into a toxic compound called MPP+, which accumulates in and damages dopaminergic neurons. MPTP was discovered in the 1980s when a group of drug users in California developed parkinsonian symptoms after injecting a heroin-like substance contaminated with MPTP.

Since then, MPTP has been used as a research tool to study Parkinson's disease and develop new treatments. However, it is not used clinically and should be handled with caution due to its toxicity.

The Globus Pallidus is a structure in the brain that is part of the basal ganglia, a group of nuclei associated with movement control and other functions. It has two main subdivisions: the external (GPe) and internal (GPi) segments. The GPe receives input from the striatum and sends inhibitory projections to the subthalamic nucleus, while the GPi sends inhibitory projections to the thalamus, which in turn projects to the cerebral cortex. These connections allow for the regulation of motor activity, with abnormal functioning of the Globus Pallidus being implicated in various movement disorders such as Parkinson's disease and Huntington's disease.

Hypokinesia is a term used in medicine to describe decreased or reduced mobility and amplitude of movements. It can be seen in various medical conditions, most notably in Parkinson's disease. In this condition, hypokinesia manifests as bradykinesia (slowness of movement), akinesia (absence of movement), or both. Hypokinesia can also affect facial expressions, leading to a mask-like appearance. Other causes of hypokinesia include certain medications, stroke, and other neurological disorders.

Muscle rigidity is a term used to describe an increased resistance to passive movement or muscle tone that is present at rest, which cannot be overcome by the person. It is a common finding in various neurological conditions such as Parkinson's disease, stiff-person syndrome, and tetanus. In these conditions, muscle rigidity can result from hyperexcitability of the stretch reflex arc or abnormalities in the basal ganglia circuitry.

Muscle rigidity should be distinguished from spasticity, which is a velocity-dependent increase in muscle tone that occurs during voluntary movement or passive stretching. Spasticity is often seen in upper motor neuron lesions such as stroke or spinal cord injury.

It's important to note that the assessment of muscle rigidity requires a careful physical examination and may need to be evaluated in conjunction with other signs and symptoms to determine an underlying cause.

The subthalamic nucleus (STN) is a small, lens-shaped structure located in the basal ganglia of the brain. It plays a crucial role in motor control and has been identified as a key target for deep brain stimulation surgery in the treatment of Parkinson's disease and other movement disorders.

The STN is involved in the regulation of movement, balance, and posture, and helps to filter and coordinate signals that are sent from the cerebral cortex to the thalamus and then on to the motor neurons in the brainstem and spinal cord. In Parkinson's disease, abnormal activity in the STN can contribute to symptoms such as tremors, rigidity, and difficulty initiating movements.

Deep brain stimulation of the STN involves implanting electrodes into the nucleus and delivering electrical impulses that help to regulate its activity. This can lead to significant improvements in motor function and quality of life for some people with Parkinson's disease.

Drug-induced dyskinesia is a movement disorder that is characterized by involuntary muscle movements or abnormal posturing of the body. It is a side effect that can occur from the long-term use or high doses of certain medications, particularly those used to treat Parkinson's disease and psychosis.

The symptoms of drug-induced dyskinesia can vary in severity and may include rapid, involuntary movements of the limbs, face, or tongue; twisting or writhing movements; and abnormal posturing of the arms, legs, or trunk. These symptoms can be distressing and negatively impact a person's quality of life.

The exact mechanism by which certain medications cause dyskinesia is not fully understood, but it is thought to involve changes in the levels of dopamine, a neurotransmitter that plays a key role in regulating movement. In some cases, adjusting the dose or switching to a different medication may help alleviate the symptoms of drug-induced dyskinesia. However, in severe cases, additional treatments such as deep brain stimulation or botulinum toxin injections may be necessary.

Bipolar disorder, also known as manic-depressive illness, is a mental health condition that causes extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). When you become depressed, you may feel sad or hopeless and lose interest or pleasure in most activities. When your mood shifts to mania or hypomania (a less severe form of mania), you may feel euphoric, full of energy, or unusually irritable. These mood swings can significantly affect your job, school, relationships, and overall quality of life.

Bipolar disorder is typically characterized by the presence of one or more manic or hypomanic episodes, often accompanied by depressive episodes. The episodes may be separated by periods of normal mood, but in some cases, a person may experience rapid cycling between mania and depression.

There are several types of bipolar disorder, including:

* Bipolar I Disorder: This type is characterized by the occurrence of at least one manic episode, which may be preceded or followed by hypomanic or major depressive episodes.
* Bipolar II Disorder: This type involves the presence of at least one major depressive episode and at least one hypomanic episode, but no manic episodes.
* Cyclothymic Disorder: This type is characterized by numerous periods of hypomania and depression that are not severe enough to meet the criteria for a full manic or depressive episode.
* Other Specified and Unspecified Bipolar and Related Disorders: These categories include bipolar disorders that do not fit the criteria for any of the other types.

The exact cause of bipolar disorder is unknown, but it appears to be related to a combination of genetic, environmental, and neurochemical factors. Treatment typically involves a combination of medication, psychotherapy, and lifestyle changes to help manage symptoms and prevent relapses.

The Substantia Nigra is a region in the midbrain that plays a crucial role in movement control and reward processing. It is composed of two parts: the pars compacta and the pars reticulata. The pars compacta contains dopamine-producing neurons, whose loss or degeneration is associated with Parkinson's disease, leading to motor symptoms such as tremors, rigidity, and bradykinesia.

In summary, Substantia Nigra is a brain structure that contains dopamine-producing cells and is involved in movement control and reward processing. Its dysfunction or degeneration can lead to neurological disorders like Parkinson's disease.

Oxidopamine is not a recognized medical term or a medication commonly used in clinical practice. However, it is a chemical compound that is often used in scientific research, particularly in the field of neuroscience.

Oxidopamine is a synthetic catecholamine that can be selectively taken up by dopaminergic neurons and subsequently undergo oxidation, leading to the production of reactive oxygen species. This property makes it a useful tool for studying the effects of oxidative stress on dopaminergic neurons in models of Parkinson's disease and other neurological disorders.

In summary, while not a medical definition per se, oxidopamine is a chemical compound used in research to study the effects of oxidative stress on dopaminergic neurons.

A tremor is an involuntary, rhythmic muscle contraction and relaxation that causes a shaking movement. It's a type of motion disorder that can affect any part of your body, but it most often occurs in your hands. Tremors can be harmless, but they can also be a symptom of a more serious neurological disorder. The cause of tremors isn't always known, but they can be the result of damage to the brain from a stroke, multiple sclerosis, or trauma. Certain medications, alcohol abuse, and drug withdrawal can also cause tremors. In some cases, tremors may be inherited and run in families.

Tremors can be classified based on their cause, appearance, and the situation in which they occur. The two most common types of tremors are:

* Resting tremors, which occur when your muscles are relaxed, such as when your hands are resting on your lap. Parkinson's disease is a common cause of this type of tremor.
* Action tremors, which occur with purposeful movement, such as when you're trying to hold something or when you're using a utensil. Essential tremor, the most common type of tremor, is an action tremor.

Tremors can also be classified based on their frequency (how often they occur) and amplitude (the size of the movement). High-frequency tremors are faster and smaller in amplitude, while low-frequency tremors are slower and larger in amplitude.

In general, tremors are not a life-threatening condition, but they can be embarrassing or make it difficult to perform daily activities. In some cases, tremors may indicate a more serious underlying condition that requires treatment. If you're concerned about tremors or have any questions about your symptoms, it's important to speak with a healthcare provider for an accurate diagnosis and appropriate treatment.

Extrapyramidal tracts are a part of the motor system that lies outside of the pyramidal tracts, which are responsible for controlling voluntary movements. These extrapyramidal tracts consist of several different pathways in the brain and spinal cord that work together to regulate and coordinate involuntary movements, muscle tone, and posture.

The extrapyramidal system includes structures such as the basal ganglia, cerebellum, and brainstem, and it helps to modulate and fine-tune motor activity. Disorders of the extrapyramidal tracts can result in a variety of symptoms, including rigidity, tremors, involuntary movements, and difficulty with coordination and balance.

Some common conditions that affect the extrapyramidal system include Parkinson's disease, Huntington's disease, and drug-induced movement disorders. Treatment for these conditions may involve medications that target specific components of the extrapyramidal system to help alleviate symptoms and improve function.

Dyskinesias are a type of movement disorder characterized by involuntary, erratic, and often repetitive muscle movements. These movements can affect any part of the body and can include twisting, writhing, or jerking motions, as well as slow, writhing contortions. Dyskinesias can be caused by a variety of factors, including certain medications (such as those used to treat Parkinson's disease), brain injury, stroke, infection, or exposure to toxins. They can also be a side effect of some medical treatments, such as radiation therapy or chemotherapy.

Dyskinesias can have a significant impact on a person's daily life, making it difficult for them to perform routine tasks and affecting their overall quality of life. Treatment for dyskinesias depends on the underlying cause and may include medication adjustments, surgery, or physical therapy. In some cases, dyskinesias may be managed with the use of assistive devices or by modifying the person's environment to make it easier for them to move around.

A mental disorder is a syndrome characterized by clinically significant disturbance in an individual's cognition, emotion regulation, or behavior. It's associated with distress and/or impaired functioning in social, occupational, or other important areas of life, often leading to a decrease in quality of life. These disorders are typically persistent and can be severe and disabling. They may be related to factors such as genetics, early childhood experiences, or trauma. Examples include depression, anxiety disorders, bipolar disorder, schizophrenia, and personality disorders. It's important to note that a diagnosis should be made by a qualified mental health professional.

The corpus striatum is a part of the brain that plays a crucial role in movement, learning, and cognition. It consists of two structures called the caudate nucleus and the putamen, which are surrounded by the external and internal segments of the globus pallidus. Together, these structures form the basal ganglia, a group of interconnected neurons that help regulate voluntary movement.

The corpus striatum receives input from various parts of the brain, including the cerebral cortex, thalamus, and other brainstem nuclei. It processes this information and sends output to the globus pallidus and substantia nigra, which then project to the thalamus and back to the cerebral cortex. This feedback loop helps coordinate and fine-tune movements, allowing for smooth and coordinated actions.

Damage to the corpus striatum can result in movement disorders such as Parkinson's disease, Huntington's disease, and dystonia. These conditions are characterized by abnormal involuntary movements, muscle stiffness, and difficulty initiating or controlling voluntary movements.

The basal ganglia are a group of interconnected nuclei, or clusters of neurons, located in the base of the brain. They play a crucial role in regulating motor function, cognition, and emotion. The main components of the basal ganglia include the striatum (made up of the caudate nucleus, putamen, and ventral striatum), globus pallidus (divided into external and internal segments), subthalamic nucleus, and substantia nigra (with its pars compacta and pars reticulata).

The basal ganglia receive input from various regions of the cerebral cortex and other brain areas. They process this information and send output back to the thalamus and cortex, helping to modulate and coordinate movement. The basal ganglia also contribute to higher cognitive functions such as learning, decision-making, and habit formation. Dysfunction in the basal ganglia can lead to neurological disorders like Parkinson's disease, Huntington's disease, and dystonia.

Carbidopa is a peripheral decarboxylase inhibitor used in the treatment of Parkinson's disease. It works by preventing the conversion of levodopa to dopamine outside of the brain, allowing more levodopa to reach the brain and reduce the symptoms of Parkinson's disease. Carbidopa is often combined with levodopa in medication formulations and is available under various brand names, such as Sinemet.

Here are some key points about carbidopa:

* It is a peripheral decarboxylase inhibitor that prevents the conversion of levodopa to dopamine outside of the brain.
* Carbidopa is often combined with levodopa in medication formulations for the treatment of Parkinson's disease.
* By preventing the conversion of levodopa to dopamine outside of the brain, more levodopa can reach the brain and reduce the symptoms of Parkinson's disease.
* Common side effects of carbidopa include nausea, vomiting, and orthostatic hypotension.
* Carbidopa should be used under the guidance of a healthcare professional and dosed appropriately to minimize side effects and maximize therapeutic benefit.

Anxiety disorders are a category of mental health disorders characterized by feelings of excessive and persistent worry, fear, or anxiety that interfere with daily activities. They include several different types of disorders, such as:

1. Generalized Anxiety Disorder (GAD): This is characterized by chronic and exaggerated worry and tension, even when there is little or nothing to provoke it.
2. Panic Disorder: This is characterized by recurring unexpected panic attacks and fear of experiencing more panic attacks.
3. Social Anxiety Disorder (SAD): Also known as social phobia, this is characterized by excessive fear, anxiety, or avoidance of social situations due to feelings of embarrassment, self-consciousness, and concern about being judged or viewed negatively by others.
4. Phobias: These are intense, irrational fears of certain objects, places, or situations. When a person with a phobia encounters the object or situation they fear, they may experience panic attacks or other severe anxiety responses.
5. Agoraphobia: This is a fear of being in places where it may be difficult to escape or get help if one has a panic attack or other embarrassing or incapacitating symptoms.
6. Separation Anxiety Disorder (SAD): This is characterized by excessive anxiety about separation from home or from people to whom the individual has a strong emotional attachment (such as a parent, sibling, or partner).
7. Selective Mutism: This is a disorder where a child becomes mute in certain situations, such as at school, but can speak normally at home or with close family members.

These disorders are treatable with a combination of medication and psychotherapy (cognitive-behavioral therapy, exposure therapy). It's important to seek professional help if you suspect that you or someone you know may have an anxiety disorder.

Mood disorders are a category of mental health disorders characterized by significant and persistent changes in mood, affect, and emotional state. These disorders can cause disturbances in normal functioning and significantly impair an individual's ability to carry out their daily activities. The two primary types of mood disorders are depressive disorders (such as major depressive disorder or persistent depressive disorder) and bipolar disorders (which include bipolar I disorder, bipolar II disorder, and cyclothymic disorder).

Depressive disorders involve prolonged periods of low mood, sadness, hopelessness, and a lack of interest in activities. Individuals with these disorders may also experience changes in sleep patterns, appetite, energy levels, concentration, and self-esteem. In severe cases, they might have thoughts of death or suicide.

Bipolar disorders involve alternating episodes of mania (or hypomania) and depression. During a manic episode, individuals may feel extremely elated, energetic, or irritable, with racing thoughts, rapid speech, and impulsive behavior. They might engage in risky activities, have decreased sleep needs, and display poor judgment. In contrast, depressive episodes involve the same symptoms as depressive disorders.

Mood disorders can be caused by a combination of genetic, biological, environmental, and psychological factors. Proper diagnosis and treatment, which may include psychotherapy, medication, or a combination of both, are essential for managing these conditions and improving quality of life.

Dopamine agents are medications that act on dopamine receptors in the brain. Dopamine is a neurotransmitter, a chemical messenger that transmits signals in the brain and other areas of the body. It plays important roles in many functions, including movement, motivation, emotion, and cognition.

Dopamine agents can be classified into several categories based on their mechanism of action:

1. Dopamine agonists: These medications bind to dopamine receptors and mimic the effects of dopamine. They are used to treat conditions such as Parkinson's disease, restless legs syndrome, and certain types of dopamine-responsive dystonia. Examples include pramipexole, ropinirole, and rotigotine.
2. Dopamine precursors: These medications provide the building blocks for the body to produce dopamine. Levodopa is a commonly used dopamine precursor that is converted to dopamine in the brain. It is often used in combination with carbidopa, which helps to prevent levodopa from being broken down before it reaches the brain.
3. Dopamine antagonists: These medications block the action of dopamine at its receptors. They are used to treat conditions such as schizophrenia and certain types of nausea and vomiting. Examples include haloperidol, risperidone, and metoclopramide.
4. Dopamine reuptake inhibitors: These medications increase the amount of dopamine available in the synapse (the space between two neurons) by preventing its reuptake into the presynaptic neuron. They are used to treat conditions such as attention deficit hyperactivity disorder (ADHD) and depression. Examples include bupropion and nomifensine.
5. Dopamine release inhibitors: These medications prevent the release of dopamine from presynaptic neurons. They are used to treat conditions such as Tourette's syndrome and certain types of chronic pain. Examples include tetrabenazine and deutetrabenazine.

It is important to note that dopamine agents can have significant side effects, including addiction, movement disorders, and psychiatric symptoms. Therefore, they should be used under the close supervision of a healthcare provider.

Movement disorders are a group of neurological conditions that affect the control and coordination of voluntary movements. These disorders can result from damage to or dysfunction of the cerebellum, basal ganglia, or other parts of the brain that regulate movement. Symptoms may include tremors, rigidity, bradykinesia (slowness of movement), akathisia (restlessness and inability to remain still), dystonia (sustained muscle contractions leading to abnormal postures), chorea (rapid, unpredictable movements), tics, and gait disturbances. Examples of movement disorders include Parkinson's disease, Huntington's disease, Tourette syndrome, and dystonic disorders.

Dopamine is a type of neurotransmitter, which is a chemical messenger that transmits signals in the brain and nervous system. It plays several important roles in the body, including:

* Regulation of movement and coordination
* Modulation of mood and motivation
* Control of the reward and pleasure centers of the brain
* Regulation of muscle tone
* Involvement in memory and attention

Dopamine is produced in several areas of the brain, including the substantia nigra and the ventral tegmental area. It is released by neurons (nerve cells) and binds to specific receptors on other neurons, where it can either excite or inhibit their activity.

Abnormalities in dopamine signaling have been implicated in several neurological and psychiatric conditions, including Parkinson's disease, schizophrenia, and addiction.

Olivopontocerebellar atrophies (OPCA) are a group of rare, progressive neurodegenerative disorders that primarily affect the cerebellum, olive (inferior olivary nucleus), and pons in the brainstem. The condition is characterized by degeneration and atrophy of these specific areas, leading to various neurological symptoms.

The term "olivopontocerebellar atrophies" encompasses several subtypes, including:

1. Hereditary spastic paraplegia with cerebellar ataxia (SPG/ATA) - Autosomal dominant or recessive inheritance pattern.
2. Hereditary dentatorubral-pallidoluysian atrophy (DRPLA) - Autosomal dominant inheritance pattern.
3. Idiopathic OPCA - No known genetic cause, possibly related to environmental factors or spontaneous mutations.

Symptoms of olivopontocerebellar atrophies may include:

* Progressive cerebellar ataxia (gait and limb incoordination)
* Dysarthria (slurred speech)
* Oculomotor abnormalities (nystagmus, gaze palsy)
* Spasticity (stiffness and rigidity of muscles)
* Dysphagia (difficulty swallowing)
* Tremors or dystonia (involuntary muscle contractions)

Diagnosis typically involves a combination of clinical examination, neuroimaging studies (MRI), genetic testing, and exclusion of other possible causes. Currently, there is no cure for olivopontocerebellar atrophies, but supportive care can help manage symptoms and improve quality of life.

Deep brain stimulation (DBS) is a surgical procedure that involves the implantation of a medical device called a neurostimulator, which sends electrical impulses to specific targets in the brain. The impulses help to regulate abnormal brain activity, and can be used to treat a variety of neurological conditions, including Parkinson's disease, essential tremor, dystonia, and obsessive-compulsive disorder.

During the procedure, electrodes are implanted into the brain and connected to the neurostimulator, which is typically implanted in the chest. The neurostimulator can be programmed to deliver electrical impulses at varying frequencies, amplitudes, and pulse widths, depending on the specific needs of the patient.

DBS is generally considered a safe and effective treatment option for many patients with neurological conditions, although it does carry some risks, such as infection, bleeding, and hardware complications. It is typically reserved for patients who have not responded well to other forms of treatment, or who experience significant side effects from medication.

Benserazide is a type of medication called an inhibitor of peripheral aromatic amino acid decarboxylase. It is often used in combination with levodopa to treat Parkinson's disease. Benserazide works by preventing the conversion of levodopa to dopamine outside of the brain, which helps to reduce the side effects of levodopa and increase the amount of dopamine that reaches the brain. This can help to improve the symptoms of Parkinson's disease, such as stiffness, tremors, and difficulty with movement.

Benserazide is available in combination with levodopa under the brand name Madopar. It is taken orally, usually in the form of tablets. The specific dosage of benserazide will depend on the individual's needs and should be determined by a healthcare professional.

It is important to note that benserazide can interact with other medications, so it is important to inform your doctor about all the medications you are taking before starting treatment with benserazide. Additionally, benserazide may cause side effects, such as nausea, dizziness, and dry mouth. If you experience any severe or persistent side effects while taking benserazide, you should contact your healthcare provider.

Mazindol is a prescription medication that belongs to a class of drugs known as sympathomimetic amines or anorectics. It has been used in the treatment of obesity, as it works by reducing appetite and increasing the amount of energy that the body uses. Mazindol affects certain chemicals in the brain that control appetite.

It's important to note that mazindol is not commonly used today due to its potential for abuse and serious side effects. It should only be used under the close supervision of a healthcare provider, and its use is typically reserved for individuals with severe obesity who have not responded to other treatment options.

The Diagnostic and Statistical Manual of Mental Disorders (DSM) is a publication of the American Psychiatric Association (APA) that provides diagnostic criteria for mental disorders. It is widely used by mental health professionals in the United States and around the world to diagnose and classify mental health conditions.

The DSM includes detailed descriptions of symptoms, clinical examples, and specific criteria for each disorder, which are intended to facilitate accurate diagnosis and improve communication among mental health professionals. The manual is regularly updated to reflect current research and clinical practice, with the most recent edition being the DSM-5, published in 2013.

It's important to note that while the DSM is a valuable tool for mental health professionals, it is not without controversy. Some critics argue that the manual medicalizes normal human experiences and that its categories may be too broad or overlapping. Nonetheless, it remains an essential resource for clinicians, researchers, and policymakers in the field of mental health.

Atypical Parkinsonian Disorders article Romano, S.; Colosimo, C. (2001-11-27). "Procerus sign in progressive supranuclear palsy ... It is highly specific to PSP compared to other disorders involving Parkinsonism. Dystonia of the procerus muscle or the ...
2005). "Neurodegenerative α-Synucleinopathies". Atypical Parkinsonian disorders: clinical and research aspects. Springer. p. 77 ... and the Rainwater Charitable Foundation prize for outstanding innovation in neurodegenerative disorder research. He is married ...
David R. Williams & Irene Litvan (October 2013). "Parkinsonian syndromes". Continuum (Minneap Minn). 19 (5 Movement Disorders ... "Concomitant pathologies among a spectrum of parkinsonian disorders". Parkinsonism Relat Disord. 20 (5): 525-9. doi:10.1016/j. ... These disorders are currently lumped into two groups, the synucleinopathies and the tauopathies. They may coexist with other ... The latter is characterized by ataxia and dysarthria, and may occur either as an inherited disorder or as a variant of multiple ...
"Applause sign in parkinsonian disorders and Huntington's disease". Movement Disorders. 23 (16): 2307-2311. doi:10.1002/mds. ... and palmomental signs in Parkinsonian disorders. One study finds no correlation between results of a test of motor behaviour ( ... "Diagnostic accuracy of the clapping test in Parkinsonian disorders". Journal of Neurology. 254 (10): 1366-1369. doi:10.1007/ ... is it really specific for Parkinsonian disorders? Evidence from cortical dementias". Journal of Neurology, Neurosurgery & ...
Kowalska A, Jamrozik Z, Kwieciński H (2004). "Progressive supranuclear palsy--parkinsonian disorder with tau pathology". Folia ... Pittman AM, Fung HC, de Silva R (October 2006). "Untangling the tau gene association with neurodegenerative disorders". Human ... Pickering-Brown S (2004). "The tau gene locus and frontotemporal dementia". Dementia and Geriatric Cognitive Disorders. 17 (4 ... GeneReviews/NCBI/NIH/UW entry on MAPT-Related Disorders MR scans of variant CJD CSF tau-positive man Overview of all the ...
"Concomitant pathologies among a spectrum of parkinsonian disorders". Parkinsonism & Related Disorders. 20 (5): 525-9. doi: ... as opposed to the stooped-forward posture of other Parkinsonian disorders, although PSP-Parkinsonism (see below) can ... Cognitive disorders, Corticobasal syndrome, Extrapyramidal and movement disorders, Rare diseases, Syndromes). ... Fewer than 1% of those with PSP have a family member with the same disorder. A variant in the gene for tau protein called the ...
... in parkinsonian disorders". Parkinsonism % Related Disorders. 15 (3): 165-174. doi:10.1016/j.parkreldis.2008.04.033. PMID ... Receiving multiple concussions can lead to long-term memory loss, psychiatric disorders, brain damage and other neurological ... Dementia Pugilistica, more commonly known as "Punch Drunk Syndrome", is a degenerative brain disorder resulting from head ... All articles lacking reliable references, Articles lacking reliable references from January 2019, Brain disorders, Neurotrauma ...
"Biosignatures for Parkinson's Disease and Atypical Parkinsonian Disorders Patients". PLOS ONE. 7 (8): e43595. Bibcode:2012PLoSO ...
"Dopamine transporter SPECT imaging in Parkinson's disease and parkinsonian disorders". Turkish Journal of Medical Sciences. 51 ... in which a physician has found cause to more deeply investigate a patient who has or may have a neurological disorder. Common ...
Minor tongue movements can contaminate the EEG, especially in parkinsonian and tremor disorders.[citation needed] In addition ... it can be seen in generalized distribution in diffuse disorder or metabolic encephalopathy or deep midline disorders or some ... EEG used to be a first-line method of diagnosis for tumors, stroke, and other focal brain disorders, but this use has decreased ... An EEG might also be helpful for diagnosing or treating the following disorders: Brain tumor Brain damage from head injury ...
Parkinsonian syndromes are a group of movement disorders characterized by classical motor symptoms such as tremors, ... Extrapyramidal and movement disorders, Rare diseases, Neurodegenerative disorders, Peripheral nervous system disorders). ... "Reduced genital sensitivity in female patients with multiple system atrophy of parkinsonian type". Movement Disorders. 18 (4): ... abnormal breathing or inspiratory stridor during sleep other sleep disorders including sleep apnea, REM behavior disorder ...
Parkinsonian syndromes are a group of movement disorders characterized by classical motor symptoms such as tremors, ... The person with DLB may experience disorders of wakefulness or sleep disorders (in addition to REM sleep behavior disorder) ... REM sleep behavior disorder and dementia with Lewy bodies "REM sleep behavior disorder (RBD) has been studied more thoroughly ... Sleep disorders (disrupted sleep cycles, sleep apnea, and arousal from periodic limb movement disorder) are common in DLB and ...
Parkinsonian syndromes are a group of movement disorders characterized by classical motor symptoms such as tremors, ... Fabrizi, Monaco, Dalla Libera (2004). "Parkinsonian syndrome following MDMA (Ecstasy) addiction". Movement Disorders. 19: S73- ... Movement Disorders. Vancouver, British Columbia, Canada: International Parkinson and Movement Disorder Society/Wiley. 13 (3): ... Tse W, Cersosimo MG, Gracies JM, Morgello S, Olanow CW, Koller W (August 2004). "Movement disorders and AIDS: a review". ...
... induced side effects in Parkinsonian patients". Movement Disorders. 32 (4): 628-629. doi:10.1002/mds.26953. PMC 5412843. PMID ... "Adaptive deep brain stimulation in a freely moving parkinsonian patient". Movement Disorders. 30 (7): 1003-1005. doi:10.1002/ ... "Responsive Deep Brain Stimulator for Essential Tremor , National Institute of Neurological Disorders and Stroke". www.ninds.nih ... Beudel, Martijn; Cagnan, Hayriye; Little, Simon (November 18, 2018). "Adaptive Brain Stimulation for Movement Disorders". ...
This disorder is caused by a deficiency of dopamine in the basal ganglia circuit leading to motor deficits. Gait is one of the ... Parkinsonian gait (or festinating gait, from Latin festinare [to hurry]) is the type of gait exhibited by patients with ... Parkinsonian gait is characterized by small shuffling steps and a general slowness of movement (hypokinesia), or even the total ... February 1990). "Parkinsonian abnormality of foot strike: a phenomenon of ageing and/or one responsive to levodopa therapy?". ...
Tourette syndrome or Tic disorder. Epilepsy or Seizure disorder. Parkinsonian syndrome features such as tremors, stiff ... Neurological sleep disorders such as narcolepsy, insomnia, circadian rhythm disorder, etc. Conditions affecting perceptions and ... Because these are frequently found in cases of autistic disorders, criteria could be met for multiple neurological disorders, ... Various neuropsychological disorders can also be found in family members of people with MCDD. Cohen, D. J.; Paul, R.; Volkmar, ...
"Unilateral caudal zona incerta deep brain stimulation for Parkinsonian tremor". Parkinsonism & Related Disorders. 18 (10): 1062 ... In the disorder, men tend to display more rigidity and women more bradykinesic motor behavior. Age of onset Hypokinesia is ... It is also associated with mental health disorders and prolonged inactivity due to illness, amongst other diseases. The other ... Hypokinesia describes a variety of more specific disorders: The most common cause of Hypokinesia is Parkinson's disease, and ...
4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques". Movement Disorders. 34 (5): 708-716. doi:10.1002/mds. ... Huntington Study Group". Movement Disorders. 11 (2): 136-142. March 1996. doi:10.1002/mds.870110204. ISSN 0885-3185. PMID ... activation of the S1R is a promising therapeutic target for treating neurodegenerative and neurodevelopmental disorders. ...
... emphasizing non-Parkinsonian disorders. The journal is published by Ubiquity Press and was established in 2011 by the current ... Movements is a peer-reviewed open access medical journal covering neurology with a focus on hyperkinetic movement disorders ...
... induced side effects in Parkinsonian patients - PMC". Movement Disorders. 32 (4): 628-629. doi:10.1002/mds.26953. PMC 5412843. ... Along with discussing the efficacy of deep brain stimulation (DBS) in terms of treating neurological disorders, Priori has ... The company is dedicated to the development of neurotechnological devices for the treatment of neurological disorders. Priori ... Priori's research spans the fields of clinical and experimental neurosciences with particular attention on movement disorders ...
see video) Parkinsonian-Pyramidal syndrome (PPS) is a combination of both pyramidal and parkinsonian signs that manifest in ... Related Disorders. 39: 4-16. doi:10.1016/j.parkreldis.2017.02.025. PMID 28256436. Babinski sign "Abnormal pyramidal signs ( ... Tranchant, Christine; Koob, Meriam; Anheim, Mathieu (June 2017). "Parkinsonian-Pyramidal syndromes: A systematic review". ...
Hornykiewicz, O. (2006). "The discovery of dopamine deficiency in the parkinsonian brain". Parkinson's Disease and Related ... Disorders. pp. 9-15. doi:10.1007/978-3-211-45295-0_3. ISBN 978-3-211-28927-3. PMID 17017502. {{cite book}}: ,journal= ignored ( ...
Agonists at higher doses have also been related to a wide variety of impulse-control disorders. Apomorphine, which is a ... Neuroablative lesion surgery locates and destroys, by heat, the parts of the brain associated with producing Parkinsonian ... One of the most widely practiced treatments for speech disorders associated with Parkinson's disease is the Lee Silverman voice ... One of the most widely practiced treatments for speech disorders associated with Parkinson's disease is the Lee Silverman voice ...
... parkinsonian disorders MeSH C10.228.140.079.862.400 - lewy body disease MeSH C10.228.140.079.862.500 - parkinson disease MeSH ... headache disorders MeSH C10.228.140.546.399 - headache disorders, primary MeSH C10.228.140.546.399.750 - migraine disorders ... parkinsonian disorders MeSH C10.228.662.600.200 - lewy body disease MeSH C10.228.662.600.400 - parkinson disease MeSH C10.228. ... sleep disorders, circadian rhythm MeSH C10.886.425.200.500 - jet lag syndrome MeSH C10.886.425.800 - sleep disorders, intrinsic ...
... including emotional lability Parkinsonian (extrapyramidal) movement disorders papilledema Hyperuricemia and hyperuricosuria. ... Treatment is first targeted at the specific metabolic disorder. In general, rasburicase and hydration are the mainstays of ... ISBN 978-1-4557-2865-7. Viera AJ, Wouk N (September 2015). "Potassium Disorders: Hypokalemia and Hyperkalemia". American Family ... Blood disorders, Conditions of the subcutaneous fat, Oncological emergencies, Syndromes). ...
... in adults demonstrated significantly improved stuttering symptoms with no reports of parkinsonian-like movement disorders or ... language or learning disability seizure disorders social anxiety disorder speech sound disorders other developmental disorders ... Other disorders with symptoms resembling stuttering, or associated disorders include autism, cluttering, Parkinson's disease, ... These associated disabilities include: Attention deficit hyperactivity disorder (ADHD): A disorder characterized by problems ...
His main area of interest is neurodegenerative diseases, such as Huntington disease, Parkinsonian disorders (including ... "Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes". Mov Disord. 25 (9): 1284-8 ...
Karl Golser Foundation (Facebook) promoting the discovery of disease modifying therapies in atypical parkinsonian disorders The ... In addition to caring for patients with Parkinsonian syndromes and dementia, his clinical activities also include the work up ... a German neurologist best known for his clinical and scientific work in Parkinson's disease and atypical Parkinsonian disorders ... Gabor Kovacs (University of Toronto) in 2018 for their landmark discoveries in the field of neurodegenerative disorders. In ...
... as a nervous system disease in two listings one as a basal ganglia Parkinsonian movement disorder and the other under brain ... The presence of Lewy bodies is a link between these disorders; the term 'diseases with Lewy bodies' therefore may be more ... The fifth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) gives Lewy body disease as the ... Galasko D (May 2017). "Lewy Body Disorders". Neurol Clin. 35 (2): 325-38. doi:10.1016/j.ncl.2017.01.004. PMC 5912679. PMID ...
Movement Disorders. 20 (8): 932-6. doi:10.1002/mds.20370. PMID 15791634. S2CID 46098045. Grégoire L, Samadi P, Graham J, Bédard ... and has also shown efficacy in reducing dyskinesias resulting from long-term anti-Parkinsonian treatment with levodopa. In June ... Related Disorders. 15 (6): 445-52. doi:10.1016/j.parkreldis.2008.11.001. PMID 19196540. "Merck KGaA: Development of Sarizotan ... "Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys". ...
MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic ... As an iron chaperone, it has excellent potential to treat Parkinsons disease as well as various Parkinsonian disorders such as ... The Companys lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug ... Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder. Tweet ...
Autonomic investigation is of value in diagnosing PD and differentiating PD from other parkinsonian disorders, such as MSA. ... Autonomic dysfunction in other parkinsonian disorders. Multiple system atrophy. Multiple system atrophy (MSA) is characterised ... The patterns of autonomic features in PD are different from other parkinsonian disorders. Detection of autonomic dysfunction ... unlike other parkinsonian disorders such as MSA, it is usually asymptomatic in the early stages and features in the advance ...
Unstructured Eye Tracking as a Diagnostic and Prognostic Biomarker in Parkinsonian Disorders. December 10, 2022. checkorphan ... Unstructured Eye Tracking as a Diagnostic and Prognostic Biomarker in Parkinsonian Disorders Study of Comprehensive ANd ... in Parkinsonian Syndromes ADDIA Proof-of-Performance Clinical Study Defining Phenotypes of Movement Disorders :Parkinsons Plus ... In-Home Care for Patients With PSP and Related Disorders Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes ...
"Parkinsonian Disorders" by people in this website by year, and whether "Parkinsonian Disorders" was a major or minor topic of ... "Parkinsonian Disorders" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Parkinsonian Disorders" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Parkinsonian Disorders". ...
Levy RHazrati LNHerrero MT et al Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states ... Levy RHazrati LNHerrero MT et al Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states ... Six months after surgery, parkinsonian motor disability (Unified Parkinsons Disease Rating Scale part III)13 was improved by ... Pollak PBenabid ALLimousin P et al Subthalamic nucleus stimulation alleviates akinesia and rigidity in parkinsonian patients. ...
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder. May 30, 2023. May 30, 2023. Alterity ... MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic ... As an iron chaperone, it has excellent potential to treat Parkinsons disease as well as various Parkinsonian disorders such as ... The Companys lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug ...
1 Department of Neurology, Parkinsons Disease and Movement Disorders Center, University of South Florida, Tampa, FL 33606, USA ... 123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes J Neuroimaging. 2012 Jul;22(3):225- ... Study 2 was a trial of [(123)I]FP-CIT SPECT in patients with established diagnoses of parkinsonian syndrome (PS) or essential ...
... a panel of 13 biomarkers that can not only detect depression but also predict who might go on to develop bipolar disorder. The ... School of Medicines Alexander Niculescu analyzed blood samples from an initial cohort of 44 people with a mood disorder to ...
This paper presents a method for an automated Parkinsonian disorders classification using Support Vector Machines (SVMs). ... Support Vector Machines; Feature selection; Binary classification; Multi-class classification; Parkinsonian disorders ... Binary and Multi-class Parkinsonian Disorders Classification Using Support Vector Machines. In: Pattern Recognition and Image ... used as a preprocessing step in order to asses the significance of the different features in diagnosing Parkinsonian disorders ...
Atypical Parkinsonian Disorders article Romano, S.; Colosimo, C. (2001-11-27). "Procerus sign in progressive supranuclear palsy ... It is highly specific to PSP compared to other disorders involving Parkinsonism. Dystonia of the procerus muscle or the ...
... is an acquired disorder of cognitive and behavioral impairment that markedly interferes with social and occupational ... Other disorders. Other disorders to consider in the differential diagnosis of AD include the following:. * Age-associated ... Neurocognitive Disorders. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American ... Contribution of alcohol use disorders to the burden of dementia in France 2008-13: a nationwide retrospective cohort study. ...
Understanding Parkinsonian Disorders , #TomorrowsDiscoveries. Play video: Living a Fuller Life with HIV , #TomorrowsDiscoveries ...
Blood-based NfL - A biomarker for differential diagnosis of parkinsonian disorder. Posted at 12:35h in Blog by pbneurodev 0 ... and atypical parkinsonian disorders (APD) with equally high diagnostic accuracy as CSF NfL, and can therefore improve the ... diagnostic workup of parkinsonian disorders. Methods: The study included 3 independent prospective... ...
They include a progressive gait disorder and, in some patients, a parkinsonian syndrome. The patient is confined to bed in ... Eating/swallowing disorders. Eating disorders with progressive dysphagia and frequent choking may be observed initially but are ... Motor disorders. Motor disorders become apparent in the middle and advanced stages of the disease. ... Communication/speech disorder: Early indication of the impairment was observed after an average of 1.4 years (range, 0-4 y; 0 ...
Discriminating Parkinsonian disorders using fluid biomarkers to improve early diagnosis. 513. Mossink, B. (2021). The cell-type ... Molecular mechanisms underlying Tourettes disorder and obsessive-compulsive disorder: insights from animal and human studies ... Autism Spectrum Disorders in High functioning Adolescents; Diagnostic considerations (AHA). 283. De Voogd, L. (2017) Do you ... Autism spectrum disorders in early childhood; Presentation, risk factors and trajectories. 285. Klemann, C. (2017) A molecular ...
Structural Correlates of Cognitive and Motor Dysfunction in Parkinsonian Disorders. PI: Kathleen Poston, MD, MS. Study Status: ... Autonomic Disorders. *Our Team*Research*Clinical Trials*Publications*Fellowship*News & Events*Make a Gift*Contact Us ... Movement Disorders Center. *Our Team*Research*CurePSP Center of Care at Stanford *Lewy Body Dementia Research Center of ... Neuromuscular Disorders. *Our Team *Fellowships*Research*Peripheral Nerve Surgery*Clinical Trials*News*Events*Videos/ ...
... is a progressive neurodegenerative disorder characterized by distal (i.e., tremor, bradykinesia, and rigidity) and axial motor ... D. Grabli, C. Karachi, E. Folgoas, M. Monfort, D. Tande, S. Clark, et al., Gait disorders in parkinsonian monkeys with ... C.H. Tai, M.K. Pan, J.J. Lin, C.S. Huang, Y.C. Yang, C.C. Kuo, Subthalamic discharges as a causal determinant of parkinsonian ... C.G. Goetz, B.C. Tilley, S.R. Shaftman, G.T. Stebbins, S. Fahn, P. Martinez-martin, et al., Movement disorder society-sponsored ...
One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal ... Parkinsonian Disorders (Parkinsonism) 08/27/1949 - "Artane therapy for parkinsonism; a preliminary study of results in 117 ... One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal ... movement disorders and as an antispasmodic.. Also Known As: Artane; AHP Brand of Trihexyphenidyl Hydrochloride; Apo-Trihex; ...
They include a progressive gait disorder and, in some patients, a parkinsonian syndrome. The patient is confined to bed in ... Eating/swallowing disorders. Eating disorders with progressive dysphagia and frequent choking may be observed initially but are ... Motor disorders. Motor disorders become apparent in the middle and advanced stages of the disease. ... Communication/speech disorder: Early indication of the impairment was observed after an average of 1.4 years (range, 0-4 y; 0 ...
Loss of dopamine results in Parkinsonian conditions, a degenerative neuromuscular disorder.. *Most antipsychotic drugs work by ... Attention Deficit and Hyperactivity Disorder (ADHD) may involve, in part, decreased dopamine activity, where parts of the brain ...
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-70. ... Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc scientific committee. Mov Disord 1998;13(Suppl l3):2-23. ... Parkinsonian syndrome in a patient with a pterional meningioma: case report and review of the literature. Clin Neurol Neurosurg ... Two movement disorder specialists (AJL and DGG) were asked to suggest the likely clinical diagnosis based on video footage. ...
2013). Automated, high accuracy classification of parkinsonian disorders: a pattern recognition approach. PLoS ONE 8:e69237. ... or self-report history questionnaire to rule out neurological disorders, such as ASD, ADHD, or Tourettes Disorder, that could ... Kana, R. K., and Just, M. A. (2011). "Autism as a disorder of functional brain connectivity," in Handbook of Autism Spectrum ... Just, M. A., Keller, T. A., Malave, V. L., Kana, R. K., and Varma, S. (2012). Autism as a neural systems disorder: a theory of ...
Parkinsonian syndromes are a group of movement disorders characterized by classical motor symptoms such as tremors, ... Extrapyramidal and movement disorders, Rare diseases, Neurodegenerative disorders, Peripheral nervous system disorders). ... "Reduced genital sensitivity in female patients with multiple system atrophy of parkinsonian type". Movement Disorders. 18 (4): ... abnormal breathing or inspiratory stridor during sleep other sleep disorders including sleep apnea, REM behavior disorder ...
Parkinsonian syndromes are a group of movement disorders characterized by classical motor symptoms such as tremors, ... Fabrizi, Monaco, Dalla Libera (2004). "Parkinsonian syndrome following MDMA (Ecstasy) addiction". Movement Disorders. 19: S73- ... "Movement Disorders. Vancouver, British Columbia, Canada: International Parkinson and Movement Disorder Society/Wiley. 13 (3): ... "Journal of Movement Disorders. 8 (3): 141-143. doi:10.14802/jmd.15021. ISSN 2005-940X. PMC 4572665. PMID 26413242.. ...
Combined total α-synuclein and phosphoserine 129 α-synuclein levels might distinguish different parkinsonian disorders (44). ... cognitive and neuropsychiatric disorders, and sleep disorders, among others (3). Neuropathologically, PD is characterized by ... Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A. 2002;99(22):14524-14529. ... This work was supported by grants from the National Institute of Neurological Disorders and Stroke (NINDS, NIH) (NS38377, the ...
Wu LJ, Sitburana O, Davidson A, Jankovic J. Applause sign in Parkinsonian disorders and Huntingtons disease. Mov Disord. 2008 ... Alberto J Espay, MD, MSc is a member of the following medical societies: American Academy of Neurology and Movement Disorders ... In other instances, testing for HIV or connective tissue disorders is indicated. ... high specificity of 18F-FDG-PET can enable exclusion of psychiatric and other neurodegenerative disorders. The 18F-FDG-PET ...
MSA is a rare and highly debilitating Parkinsonian disorder.. "The regulatory approvals in France and Austria will allow us to ... MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic ... As an iron chaperone, it has excellent potential to treat Parkinsons disease as well as various Parkinsonian disorders such as ... The Companys lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug ...
A biomarker for differential diagnosis of parkinsonian disorder. Oskar Hansson, Shorena Janelidze, Sara Hall et al.. Neurology ... AD-the most common form of dementia-and FTD spectrum disorders-an example of rarer dementias-are used here to illustrate ... Despite differences in clinical and behavioral characteristics, these disorders have shared pathologies and face common ... for its potential in treating anhedonia in major depressive disorder and used fMRI activation in the ventral striatum as a ...
Parkinsonian Disorders. Basal Ganglia Diseases. Brain Diseases. Central Nervous System Diseases. Nervous System Diseases. ... Subject has evidence of Clinically significant neurologic or other disorder or impairment that, in opinion of Investigator, is ...
  • Atypical Parkinsonian Disorders article Romano, S. (wikipedia.org)
  • Objective: To determine if blood neurofilament light chain (NfL) protein can discriminate between Parkinson disease (PD) and atypical parkinsonian disorders (APD) with equally high diagnostic accuracy as CSF NfL, and can therefore improve the diagnostic workup of parkinsonian disorders. (palmbeachneurological.com)
  • Atypical Parkinsonian disorders are progressive diseases that present with some of the signs and symptoms of Parkinsons disease, but that generally do not respond well to drug treatment with levodopa. (parkinsonsdaily.com)
  • Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised by motor dysfunction (parkinsonism) and several non-motor features. (bmj.com)
  • Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. (sdsu.edu)
  • It is highly specific to PSP compared to other disorders involving Parkinsonism. (wikipedia.org)
  • In this study, the clinical features of patients with tremor and parkinsonism were assessed by two blinded movement disorder specialists (DGG and AJL). (bmj.com)
  • Multiple system atrophy (MSA) is a rare neurodegenerative disorder characterized by autonomic dysfunction, tremors, slow movement, muscle rigidity, and postural instability (collectively known as parkinsonism) and ataxia. (wikipedia.org)
  • Parkinsonism & Related Disorders. (parkinson-gesellschaft.de)
  • Community-dwelling older adults (n = 559, median age 85, range 80-102 years) were examined regarding MPS, possible parkinsonism (PP) and subthreshold parkinsonism (SP) according to four previously used definitions and concerning the impact of parkinsonian signs on cognitive, physical, and autonomic function. (lu.se)
  • The aim of this review is to describe aspects of autonomic dysfunction, including symptoms, assessment and pathophysiology, resulting from autonomic impairment in PD and other parkinsonian syndromes. (bmj.com)
  • Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes. (nih.gov)
  • Probabilistic prediction of neurological disorders with a statistical assessment of neuroimaging data modalities. (eurecom.fr)
  • Neurological disorders are key applications with a long clinical tradition of combining functional information from nuclear medicine images with structural information from magnetic resonance imaging (MRI) to allow adequate quantification across the brain. (researchsquare.com)
  • For many neurological disorders, prediction of disease state is an important clinical aim. (projecteuclid.org)
  • This paper reports a statistical assessment of multiple neuroimaging modalities applied to the discrimination of three Parkinsonian neurological disorders from one another and healthy controls, showing promising predictive performance of disease states when compared to nonprobabilistic classifiers based on multiple modalities. (projecteuclid.org)
  • M. Filippone, A. F. Marquand, C. R. V. Blain, S. C. R. Williams, J. Mourão-Miranda, M. Girolami "Probabilistic prediction of neurological disorders with a statistical assessment of neuroimaging data modalities," The Annals of Applied Statistics, Ann. (projecteuclid.org)
  • Movement disorders are neurological conditions that involuntarily change the speed, presence, or coordination of movement. (dukehealth.org)
  • Doctors typically diagnose movement disorders based on your symptoms, a complete medical history, and physical and neurological exams. (dukehealth.org)
  • The research was funded by NIH's National Institute of Neurological Disorders and Stroke (NINDS). (nih.gov)
  • This study is an example of how brain imaging biomarkers can be used to monitor the progression of Parkinson's disease and other neurological disorders. (nih.gov)
  • NIH's National Institute of Neurological Disorders and Stroke. (nih.gov)
  • Study 2 was a trial of [(123)I]FP-CIT SPECT in patients with established diagnoses of parkinsonian syndrome (PS) or essential tremor (ET). (nih.gov)
  • Progressive supranuclear palsy is a form of atypical parkinsonian syndrome, also known as a Parkinson-plus disorder, according to the National Institutes of Health. (wtop.com)
  • The classical description of JE includes a parkinsonian syndrome with mask-like facies, tremor, cogwheel rigidity, and choreoathetoid movements. (cdc.gov)
  • Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by distal (i.e., tremor, bradykinesia, and rigidity) and axial motor symptoms (i.e., gait and postural disturbances). (springer.com)
  • Background This study examines the clinical accuracy of movement disorder specialists in distinguishing tremor dominant Parkinson's disease (TDPD) from other tremulous movement disorders by the use of standardised patient videos. (bmj.com)
  • Patients and methods Two movement disorder specialists were asked to distinguish TDPD from patients with atypical tremor and dystonic tremor, who had no evidence of presynaptic dopaminergic deficit (subjects without evidence of dopaminergic deficit (SWEDDs)) according to 123 I-N-ω-fluoro-propyl- 2β-carbomethoxy-3β-(4-iodophenyl) nortropane ([ 123 I] FP-CIT) single photon emission computed tomography (SPECT), by 'blinded' video analysis in 38 patients. (bmj.com)
  • Conclusion Clinical distinction of TDPD from atypical tremor, monosymptomatic rest tremor and dystonic tremor can be difficult due to the presence of parkinsonian features in tremulous SWEDD patients. (bmj.com)
  • However, those with MSA generally show little response to the dopamine medications used to treat Parkinson's disease and only about 9% of MSA patients with tremor exhibit a true parkinsonian pill-rolling tremor. (wikipedia.org)
  • Treatment depends on the cause and type of tremor and may involve avoidance of triggers (physiologic), propranolol or primidone (essential), physical therapy (cerebellar), levodopa (parkinsonian), and possibly deep brain stimulation or thalamotomy (disabling and drug-refractory). (msdmanuals.com)
  • The severity of tremor may not be related to the seriousness of the underlying disorder. (msdmanuals.com)
  • Neural dysfunction or lesions that cause tremor may result from injury, ischemia, metabolic abnormalities, or a neurodegenerative disorder. (msdmanuals.com)
  • Our specialized Movement Disorders Center is located at Duke Neurology Morreene Road. (dukehealth.org)
  • Researchers from Lund University have discovered a promising biomarker for Parkinson's disease and other disorders that involve dopamine deficiency in the brain. (expresshealthcaremgmt.com)
  • 2023). DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. (expresshealthcaremgmt.com)
  • We found that if a patient has a disorder in the dopamine system, the levels of the biomarker DDC increase, regardless of where they are in the course of the disease. (lu.se)
  • As an iron chaperone, it has excellent potential to treat Parkinson's disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). (tmcnet.com)
  • A movement disorders specialist assessed the workers using the Unified Parkinson's Disease Rating Scale (UPDRS) motor subscore 3 (UPDRS3). (cdc.gov)
  • This groundbreaking research provides hope for improved diagnostics and personalized treatment for patients with Parkinson's disease and other dopamine-related disorders. (expresshealthcaremgmt.com)
  • As designated Centers of Excellence for both Parkinson's disease and Huntington's disease, Duke Health provides the highest level of testing, diagnosis, and management services for people with these and other movement disorders. (dukehealth.org)
  • Researchers measured brain activity in patients with Parkinson's disease and 2 Parkinson's-like disorders over a year. (nih.gov)
  • Other disorders can cause symptoms similar to those of Parkinson's disease. (nih.gov)
  • Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease (AD), with an overall prevalence of 300 per 100,000 [ 1 ] that rises from 41 in the 40-49 years' age range to 1903 in people older than age of 80 years [ 2 ]. (hindawi.com)
  • Parkinson's disease is a brain disorder that causes unintended or uncontrollable movements, such as shaking, stiffness and difficulty with balance and coordination. (wtop.com)
  • Mild parkinsonian signs (MPS) have been characterized by several definitions, using the motor part of the Unified Parkinson's Disease Rating Scale (UPDRS). (lu.se)
  • Detection of autonomic dysfunction may therefore be helpful in diagnosing PD in the early or pre-motor stages, and/or in differentiating it from other parkinsonian disorders, such as multiple system atrophy and progressive supuranuclear palsy. (bmj.com)
  • Multiple system atrophy (MSA) is a slowly progressive disorder that affects the nerves in the brain and spinal cord (central nervous system) as well as those that extend from the spinal cord out to the body's organs (autonomic nervous system). (nih.gov)
  • ALS is part of a cluster of disorders known as motor neuron diseases that involve gradual degeneration and death of motor neurons. (parkinsonsdaily.com)
  • Our comprehensive care team works together to identify movement disorders that are difficult to diagnose, including rare genetic diseases. (dukehealth.org)
  • PD has been traditionally considered as a pure movement disorder secondary to focal degeneration of dopaminergic neurons in the substantia nigra, but, in recent years, the clinical phenotype has been better illuminated, showing that PD is a multisystem neurodegenerative disorder with motor and nonmotor features (Table 1 ) [ 3 ]. (hindawi.com)
  • The locus coeruleus (LC) is an important noradrenergic nucleus that has recently attracted a lot of attention because of its emerging role in cognitive and psychiatric disorders. (elifesciences.org)
  • Alzheimer disease (AD) is an acquired disorder of cognitive and behavioral impairment that markedly interferes with social and occupational functioning. (medscape.com)
  • This paper presents a method for an automated Parkinsonian disorders classification using Support Vector Machines (SVMs). (imtlucca.it)
  • Binary and multi-class classification problems are investigated and applied with the aim of automatically distinguishing the subjects with different forms of disorders. (imtlucca.it)
  • Automated, High Accuracy Classification of Parkinsonian Disorders: A Pattern Recognition Approach. (eurecom.fr)
  • A classification of sleeprelatedmovement disorders is presentedin Table 1 . (psychiatrictimes.com)
  • thecondition is rare before the age of 30.PLMS occur in a number of sleep disorders,particularly RLS, but alsonarcolepsy, REM sleep behavior disorder(RSBD), and obstructive sleep apnea.PLMS also occur in awake subjectswith RLS but only rarely in controls. (psychiatrictimes.com)
  • Wu LJ, Sitburana O, Davidson A, Jankovic J. Applause sign in Parkinsonian disorders and Huntington's disease. (medscape.com)
  • in tertiary referral movement disorder clinics there is close to 100% concordance between the final clinical diagnosis and pathological findings. (bmj.com)
  • In a community based study in Wales, 3 only 53% of patients, treated with antiparkinson therapy in primary care, met the Queen Square Brain Bank criteria for the clinical diagnosis of PD when re-examined by an experienced movement disorder specialist. (bmj.com)
  • When patients complain of sleep disturbance, psychiatrists should consider,and question for, features of nocturnal movement disorder. (psychiatrictimes.com)
  • A disruption in how these components communicate with each other can result in a movement disorder. (dukehealth.org)
  • The Duke movement disorder care team includes providers who specialize in a variety of evidence-supported interventions. (dukehealth.org)
  • Our highly trained therapists specialize in treating people with movement disorders and are a highly integrated part of our movement disorder care team. (dukehealth.org)
  • MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic instability that affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that predisposes to falls. (tmcnet.com)
  • The patterns of autonomic features in PD are different from other parkinsonian disorders. (bmj.com)
  • Neuromapping of functional deficits associated with Parkinsonian disorders Dr. Madhuri Behari , Dr. S. Senthil Kumaran, Dr. Vinay Goyal and Prof. Vaishna Narang. (jnu.ac.in)
  • Mental status changes, focal neurologic deficits, generalized weakness, and movement disorders might develop over the next few days. (cdc.gov)
  • Palsy of the vocal cords is an important and sometimes initial clinical manifestation of the disorder. (wikipedia.org)
  • Pollak PBenabid ALLimousin P et al Subthalamic nucleus stimulation alleviates akinesia and rigidity in parkinsonian patients. (jamanetwork.com)
  • In the journal Molecular Psychiatry last month , researchers led by Indiana University School of Medicine's Alexander Niculescu analyzed blood samples from an initial cohort of 44 people with a mood disorder to identify genes whose expression changed with differences in patients' symptoms. (genomeweb.com)
  • Magnetic Resonance quantitative markers are used as features to train SVMs with the aim of automatically diagnosing patients with different Parkinsonian disorders. (imtlucca.it)
  • The results showed that patients with a disorder in the dopamine system had increased levels of DCC, regardless of the stage of the disease. (expresshealthcaremgmt.com)
  • For DBS patients with major depressive disorder, a restoration of pre-morbid personality was associated with alleviation of illness. (philpapers.org)
  • Medications, including MAO and COMT inhibitors and dopamine agonists, increase levels of dopamine, the brain chemical that helps control symptoms like difficulty walking or tremors that occur in parkinsonian disorders. (dukehealth.org)
  • While motor abnormalities are the hallmark of Parkinsonian conditions, it is becoming apparent that there may be distinct differences regarding the motor phenotype of PD and those of other Parkinsonian disorders (DLB or PDD) [ 2 ]. (iospress.com)
  • Botulinum toxin ("Botox") injections can help reduce muscle contractions in movement disorders like dystonia. (dukehealth.org)
  • Progressive supranuclear palsy (PSP) is a rare, progressive brain disorder that causes problems with control of walking and balance. (nih.gov)
  • When considering disorders ofmovement during sleep, the physicianshould ascertain whether abnormalmovements also occur during awakeperiods. (psychiatrictimes.com)
  • Progression of falls in postmortem-confirmed parkinsonian disorders. (springer.com)
  • After testing these RNA expression markers in additional cohorts, the researchers uncovered a panel of 13 biomarkers that can not only detect depression but also predict who might go on to develop bipolar disorder. (genomeweb.com)
  • Loss of dopamine results in Parkinsonian conditions, a degenerative neuromuscular disorder. (yourtango.com)
  • Attention Deficit and Hyperactivity Disorder (ADHD) may involve, in part, decreased dopamine activity, where parts of the brain aren't working well enough to constrain attention and resist impulses. (yourtango.com)
  • According to the authors, high specificity of 18F-FDG-PET can enable exclusion of psychiatric and other neurodegenerative disorders. (medscape.com)
  • In particular, it turns out that the features selected as the most meaningful ones reflect the opinions of the clinicians as the most important markers in the diagnosis of these disorders. (imtlucca.it)
  • A ranking feature selection method is also used as a preprocessing step in order to asses the significance of the different features in diagnosing Parkinsonian disorders. (imtlucca.it)
  • Overview of Movement and Cerebellar Disorders Voluntary movement requires complex interaction of the corticospinal (pyramidal) tracts, basal ganglia, and cerebellum (the center for motor coordination) to ensure smooth, purposeful movement. (msdmanuals.com)
  • This graph shows the total number of publications written about "Parkinsonian Disorders" by people in this website by year, and whether "Parkinsonian Disorders" was a major or minor topic of these publications. (sdsu.edu)
  • Below are the most recent publications written about "Parkinsonian Disorders" by people in Profiles. (sdsu.edu)
  • The Duke Movement Disorders Center offers events to support and educate people with movement disorders and their care partners. (dukehealth.org)
  • MSA is a rare and highly debilitating Parkinsonian disorder. (yahoo.com)